Skip to content
Moleculin Biotech (MBRX) on Tuesday announced that a second round of independent laboratory testing has confirmed the antiviral activity of its drug candidate WP1122 as a potential treatment against coronavirus. The news is pushing shares up 33% to $1.46 in early market trading.Moleculin said that it contracted with IIT Research Institute for additional in vitro testing of its WP1122. The testing involved a cell viability assay in the VERO E6 cell line infected with SARS-CoV-2 and compared the therapeutic effects of 2-deoxy-D-glucose or 2-DG (the active ingredient in WP1122) alone with those of WP1122, a 2-DG prodrug. Results of a previous test earlier this year, showed that 2-DG reduced the virus that causes COVID-19 by 100% in in vitro testing."Having validation in yet another virus host cell line provides additional confidence in the antiviral activity we are seeing,” said Moleculin CEO Walter Klemp. “We are also gaining confidence that in vitro testing results...
Despite COVID-19's devastating impact on the economy, Goldman Sachs’ chief U.S. equity strategist David Kostin believes 2020 earnings might not be as bad as previously expected. Kostin gave his estimate for S&P 500 earnings per share in 2020 a lift, from $110 to $115. For 2021, the forecast remains at $170, which is 4% above 2019’s realized level, with the figure landing at $188 for 2022.That said, management commentary will be an essential factor in gauging the outlook. “Given the heightened investor focus on the earnings outlook in 2021 and 2022, we expect management commentary will prove more valuable than backward-looking results,” Kostin wrote in a recent note.As for his stock picks, the strategist argues that given the low interest rate environment, names with the longest-duration cash flow are “what you want to own.” These companies include those in the technology and healthcare sectors.Bearing this in mind, we used TipRanks’ database...
D. Jordan became the CEO of First Horizon National Corporation (NYSE:FHN) in 2008, and we think it's a good time to......
Does the July share price for OPKO Health, Inc. (NASDAQ:OPK) reflect what it's really worth? Today, we will estimate......
Since taking over as chief executive in October, Charles Scharf has shaken up leadership at the bank and installed a slew of former colleagues and confidants in top positions. Santomassimo most recently served as Scharf's CFO at Bank of New York Mellon and previously led the finance teams for various business lines at JPMorgan Chase & Co. Shrewsberry, who told Scharf he was considering retirement when he joined the company, will stay on to ensure a smooth transition, the company said....
Global med tech company Becton, Dickinson (BDX) has announced additional pandemic orders for needles and syringes from the United States and Canada totaling 177 million injection devices.The new US order for 140 million injection devices brings total U.S. orders from BD to 190 million devices. The new Canadian order for 37 million brings total Canadian orders from BD to 75 million devices. Across the world, BD has received total orders of 330 million needles and syringes from the U.S., Canada and the United Kingdom.A majority of these orders will be delivered by the end of December 2020 in anticipation of a vaccine being approved late this year or early 2021.BD adds that it does not expect these orders to impact its ability to fulfill existing customer requirements for needles and syringes, including the annual flu vaccination and childhood immunization campaigns.In addition, on July 8, BD announced a $70 million investment to expand needle and syringe production at its Nebraska facilities as part of a...
